PMID- 11326678
OWN - NLM
STAT- MEDLINE
DCOM- 20010524
LR  - 20210103
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 20
IP  - 6D
DP  - 2000 Nov-Dec
TI  - Prognostic relevance of serum vascular endothelial growth factor in ovarian 
      cancer.
PG  - 5109-12
AB  - BACKGROUND: The vascular endothelial growth factor (VEGF) is the angiogenic 
      growth factor most strongly implicated in tumor angiogenesis. Its special role in 
      the pathophysiology of ovarian cancer emerges from its dual functional capability 
      as an endothelial cell mitogen and a potent stimulator of vascular permeability, 
      leading to the characteristic ascites accumulation in this disease. The aim of 
      our study was to analyze the prognostic value of serum VEGF (sVEGF) as a tumor 
      marker in ovarian cancer. PATIENTS AND METHODS: 41 patients with ovarian 
      carcinomas were included in the study. Venous blood was taken from all patients 
      preoperatively. From 15 patients an additional postoperative blood sample was 
      drawn. sVEGF was measured in duplicate using a commercially available ELISA-kit. 
      RESULTS: The mean sVEGF level for the ovarian cancer patients was 522 +/- 321 
      pg/ml (SD) (median: 440; range: 55-1263 pg/ml) No statistically significant 
      correlation could be found between sVEGF concentration and age, histologic type 
      or FIGO-stage. sVEGF values four weeks after surgery were significantly lower 
      than those before treatment (p = 0.002). In patients after radical surgery sVEGF 
      values dropped or stayed stable below the cut-off more often than in patients 
      with residual disease. In the univariate analysis, improved overall survival (OS) 
      was found for ovarian cancer patients with a sVEGF below the cut-off value of 440 
      pg/ml (p = 0.017). sVEGF was also tested in a multivariate analysis together with 
      residual disease and FIGO-stage using the Cox's proportional hazard model. In the 
      final model only residual disease had an independent influence on OS (p = 0.018). 
      CONCLUSION: sVEGF levels decrease significantly after cytoreductive therapy and 
      might indicate treatment efficiency. According to our study, sVEGF is not an 
      independent prognosticator of survival for ovarian cancer.
FAU - Oehler, M K
AU  - Oehler MK
AD  - Universitaets-Frauenklinik, Universitaet Freiburg, Hugstetter Str. 55, D-79106 
      Freiburg, Germany. moehler@frk1.ukl.uni-freiburg.de
FAU - Caffier, H
AU  - Caffier H
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Endothelial Growth Factors)
RN  - 0 (Lymphokines)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (Vascular Endothelial Growth Factors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - Endothelial Growth Factors/*blood
MH  - Female
MH  - Humans
MH  - Lymphokines/*blood
MH  - Middle Aged
MH  - Ovarian Neoplasms/blood/*diagnosis/mortality
MH  - Prognosis
MH  - Survival Rate
MH  - Vascular Endothelial Growth Factor A
MH  - Vascular Endothelial Growth Factors
EDAT- 2001/05/01 10:00
MHDA- 2001/05/26 10:01
CRDT- 2001/05/01 10:00
PHST- 2001/05/01 10:00 [pubmed]
PHST- 2001/05/26 10:01 [medline]
PHST- 2001/05/01 10:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 2000 Nov-Dec;20(6D):5109-12.